An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development by Armstrong, Matthew D. et al.
Journal of Cancer 2011, 2 
 
 
http://www.jcancer.org 
142 
J Jo ou ur rn na al l   o of f   C Ca an nc ce er r   
2011; 2:142-152 
Research Paper 
An Effective Personalized Approach to a Rare Tumor: Prolonged Survival 
in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis 
and Cell Line Development 
Matthew D. Armstrong 1, Daniel Von Hoff 5, Bruce Barber 2, Laura A. Marlow3, Christina von Roemeling3, 
Simon J. Cooper3, Patrick Travis6, Elizabeth Campbell5, Ricardo Paz-Fumagalli4, John A. Copland3, 
Gerardo Colon-Otero1  
1.  Division of Hematology/Oncology; 
2.  Department of Laboratory Medicine and Pathology; 
3.  Department of Cancer Biology; 
4.  Department of Diagnostic Radiology, Mayo Clinic, Jacksonville, Florida, USA; 
5.  The Translational Genomics Research Institute (TGen), Phoenix AZ, USA; 
6.  Highlands Oncology Group, Bentonville AR, USA. 
 Corresponding author: Dr. Gerardo Colon-Otero, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida, 
32224. gcolonotero@mayo.edu 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.01.12; Accepted: 2011.02.23; Published: 2011.03.08 
Abstract 
Acinar cell carcinoma of the pancreas is an uncommon malignancy, accounting for less than 1% 
of all pancreatic neoplasms. Because of its rarity, only a few retrospective studies are available 
to help guide management. We report the case of a patient with metastatic ACC who 
achieved prolonged survival as a result of personalized treatment designed in part on the basis 
of molecular and in-vitro data collected on analysis of the tumor and a cell line developed from 
the liver metastasis. To our knowledge, this represents the first human cell line of ACC. The 
molecular findings on this case and this patient’s cell line may be of use in the management of 
future cases of this rare tumor and allow the identification of potential novel targets for the 
effective treatment of this disease. 
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Introduction 
Although the most common cells in the pancreas 
are the acinar cells, malignant transformation of these 
cells  is  very  rare.  Pancreatic  adenocarcinomas,  de-
rived from epithelial cells lining the pancreatic ducts 
are the most common pancreatic malignancy followed 
by neuroendocrine tumors, with acinar cell carcino-
mas (ACC) of the pancreas representing less than 1% 
of  all  pancreatic  tumors1-8.  Fewer  than  50  cases  of 
ACC  are  diagnosed  annually  in  the  USA8.  Patients 
with ACC are more likely to present at a younger age 
and with earlier stage tumors as compared to patients 
with the more common and deadlier pancreatic ade-
nocarcinomas.  ACC  affects  males  more  commonly 
than females1-8. 
There are also significant differences in the clin-
ical presentation of ACC as compared to pancreatic 
adenocarcinoma. Contrary to pancreatic adenocarci-
noma cases, patients with early stage ACC frequently 
present  with  abdominal  pain  and  bloating  as  the 
dominant  symptoms.  Occasionally,  ACC  tumors Journal of Cancer 2011, 2 
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produce excessive lipase causing systemic fat necro-
sis9-16. Clinical manifestations of this syndrome of fat 
necrosis can include panniculitis, discrete skin lesions 
and  subcutaneous  nodules.  Pathologic  fractures  re-
lated to intraosseus necrosis have been described as 
well.  Laboratory  abnormalities  include  elevated  se-
rum lipase levels, eosinophilia, and occasionally ele-
vated serum alpha fetoprotein levels. 
Because of the rarity of this malignancy, studies 
have  primarily  consisted  of  retrospective  chart  re-
views and case reports. Very limited data are availa-
ble  about  effective  systemic  treatments  for  patients 
with recurrent, unresectable or metastatic disease. The 
rarity of the disease has thus far precluded systematic 
approach to treatment through clinical trials, and only 
a handful of retrospective reviews and case reports 
describing empiric treatments have been published1-8, 
17-26. 
We  report  a  case  of  acinar  cell  carcinoma  in 
which the patient had extended survival with meta-
static disease. We attribute his extended survival to an 
aggressive  multi-disciplinary  approach  involving  a 
variety of localized and systemic treatments. Moreo-
ver,  systemic  treatments  were  guided  by  molecular 
and  phenotypic  studies  performed  on  the  patient’s 
tumor tissue biopsies and derivative cell lines. This 
multi-disciplinary approach with translational studies 
offers a potential strategy for management of acinar 
cell carcinomas in particular and rare malignancies in 
general. 
Materials and Methods  
Serum Chemistries 
Peripheral  blood  studies  were  monitored,  in-
cluding  serum  lipase,  alpha  fetoprotein,  alkaline 
phosphatase,  and  CEA  levels.  Normal  references 
range  levels  are  as  follows  for  serum  lipase  (7-60 
IU/L),  alpha  fetoprotein  (0.0  –  5.9  ng/ml),  alkaline 
phosphatase (45 – 115 IU/L) and CEA (0 – 3.0 ng/ml 
for non-smoker). 
Biopsies and Immunhistochemistry 
Since ACC is a rare cancer with no standard of 
care, biopsies were requested by the patient for the 
purpose of establishing cell lines for therapeutic drug 
testing  as  well  as  RNA  and  protein  analysis.  IRB 
permission was obtained for this procedure. Biopsies 
were  performed  using  needle  biopsies.  For  needle 
biopsies, two to three 18-gauge needle core biopsies 
were performed. For DNA MA analysis, tissue was 
immediately frozen and shipped on dry ice to a cen-
tral Clinical Laboratory Improvement Amendments- 
certified laboratory (Caris Life Sciences, Phoenix, AZ). 
For  immunohistochemistry  (IHC),  paraffin  blocks 
were  shipped  on  cold  packs.  For  IHC  studies,  the 
formalin-fixed  paraffin-embedded  tumor  samples 
had  sections  submitted  and  processed  for  standard 
IHC. IHC was performed for Her2/neu, estrogen re-
ceptor, progesterone receptor, c-kit, epidermal growth 
factor receptor (EGFR) and cyclooxygenase 2 (COX2) 
ERCC1 (DNA excision repair protein), p-glycoprotein, 
dihydrofolate  reductase  (DHFR),  TYMS,  secreted 
protein  acidic  cysteine-rich  (SPARC,  osteonectin), 
platelet  derived  growth  factor  (PDGFR)  and  topoi-
somerase II alpha (TOP2A). IHC was performed by 
Caris Life Science (Phoenix, AR). Human epidermal 
growth  factor  receptor  2  (HER2)  and  epidermal 
growth factor receptor (EGFR) were stained as speci-
fied by the vendor (DAKO, Copenhagen, Denmark). 
All other antibodies were purchased from commercial 
sources and visualized with a DAB biotin-free poly-
mer detection kit. Appropriate positive control tissue 
was used for each antibody. Negative control slides 
were stained by replacing the primary antibody with 
an  appropriately  matched  isotype-negative  control 
reagent.  All  slides  were  counterstained  with  hema-
toxylin as the final step and cover slipped. All slides 
were evaluated semiquantitatively on a scale of 0 (no 
staining) to 4+ and by the percentage of the tumor 
cells showing the reactivity by a single pathologist. 
IHC was considered positive for target if staining was 
2+ in 30% of cells.  
Gene Expression Analysis Using DNA Microarrays  
The  frozen  tumor  fragments  for  microarray 
(MA) were placed in a glass tube on 0.5 mL of frozen 
0.5 M guanidine isothiocyanate solution and thawed 
and homogenized with a Covaris S2 (Covari, Woburn, 
MA). TriZol (0.5 mL) was added and mixed, and the 
solution was heated to 65°C for 5 minutes and then 
cooled on ice and phase separated by adding chloro-
form  and  centrifugation.  An  equal  volume  of  70% 
ethanol was added to the aqueous phase, which was 
chromatographed  on  a  Qiagen  Rneasy  column  (Qi-
agen, Germantown, MD). RNA was bound and then 
eluted. RNA was tested for integrity by assessing the 
ratio of 28S to 18S ribosomal RNA on an Agilent Bi-
oAnalyzer  (Agilent,  Santa  Clara,  CA).  Tumor  RNA 
and RNA from a sample of a normal pancreas were 
converted to cDNA and labeled during T7 polymer-
ase amplification with contrasting fluor tagged (Cy3, 
Cy5) cytidine triphosphate. The labeled tumor and its 
tissue of origin reference were hybridized to an Ag-
ilent  HIAv2  60-mer  oligo  array  chip  with  17,085 
unique probes. Hybridization signals were acquired 
and  normalized  using  Agilent's  Feature  Extraction 
software (version 7.1). The MA was considered posi-
tive for a target if the difference in expression for a Journal of Cancer 2011, 2 
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gene between tumor and control organ tissue was at a 
significance level of p<0.05.  
Cell line and animal model development for acinar cell 
pancreatic cancer 
Since no standard  of care exists for acinar cell 
pancreatic cancer, the patient requested a liver biopsy 
of the tumor to attempt to develop a cell line and test 
drug sensitivity. Two such procedures occurred, one 
in May 2005 and the other in May 2008. The procedure 
was performed under local anesthetic and ultrasound 
guidance  after  obtaining  consent  from  the  patient. 
Biopsied tissue was frozen in liquid nitrogen as well 
as transported to the laboratory in sterile media and 
tissue was prepared for cell culture. Half of the tissue 
was minced, washed in PBS (Cellgro, Herndon, VA) 
and  cultured  in  DMEM  medium  (Cellgro)  supple-
mented with 10% fetal bovine serum (Hyclone, Logan, 
UT), non – essential amino acids (Cellgro), and peni-
cillin-streptomycin-amphotericin  B  (Cellgro)  at  37ºC 
in a humidified atmosphere with 5% CO2. The biop-
sied tissue collected May 2005 grew in culture up to 
passage  16.  These  primary  cells  (PanJ1)  were  drug 
tested at passage 3. Panc-4 cells were derived from a 
biopsy of a lymph node metastasis. These cells have 
been cultured up to passage 13 and used at passage 7 
for drug testing. 
The other half of the tissue was implanted sub-
cutaneously  into  two  anesthetized  athymic  nude 
mouse (Harlan Laboratories, Indianapolis, IN) under 
IACUC approved procedures in an attempt to grow 
humanized tumors. This in vivo model could then be 
used to test promising drugs identified in cell lines 
grown in culture. The biopsied tumor implanted from 
the 2005 did not result in tumor growth in mice while 
the  biopsied  tissues  from  May  2008  resulted  in  tu-
mors.  
Proliferation assays 
For growth analysis, cells were plated on day 0 
in 12-well plates (Midwest Scientific, St. Louis, MO) in 
triplicate at a concentration of 2 x 104 cells / well. On 
day  1,  cells  were  treated with  one  of  the  following 
drugs: etoposide (topoisomerse II inhibitor), cytosine 
arabinoside  (antimetabolic  agent),  bortezomib  (pro-
teasome  inhibitor),  doxorubicin  (topoisomerase 
II inhibitor),  irinotecan  (topoisomerase  I inhibitor) 
and STI571 (imatinib, receptor tyrosine kinase inhibi-
tor,  gift  from  Novartis,  Switzerland),  lapatinib 
(EGFR/HER2  inhibitor,  gift  from  GlaxoSmithKline, 
United Kingdom), CCI-779 (temsirolimus, mTOR in-
hibitor, gift from Wyeth Pfizer Pharmaceuticals, New 
York, New York) and ixabepilone (microtubule stabi-
lizer,  less  susceptible  to  P-glycoprotein  mediated 
multidrug resistance, gift from Bristol-Myers Squibb, 
New  York,  New  York).  All  other  drugs  were  pur-
chased from Sigma-Aldrich (St. Louis, MO). On day 4, 
cells were collected and counted on a Coulter Particle 
Counter (Beckman, Brea, CA). The mean and stand-
ard deviation were calculated and plotted. 
To determine synergy of combinatorial therapy, 
the concentration of each drug where 50% of growth 
is inhibited (IC50) is first determined by dose concen-
tration  curves.  Combining  the  drugs  at  a  constant 
ratio at, below and above their IC50 concentrations is 
used to determine whether their antiproliferative ac-
tivity is synergistic, additive or antagonistic. Results 
from this assay were used to calculate a combination 
index (CI) value using the software program CalcuS-
yn (BioSoft, Ferguson, MO). The CI equation in Cal-
cuSyn is based on the multiple drug-effect equation of 
Chou and Talalay (27). CI values less than 1 indicate a 
synergistic effect while CI values above 1 are indica-
tive of antagonism. 
Statistical Analysis  
Data are presented as the mean  SD and com-
parisons  of  treatment  groups  were  analyzed  by 
two–tailed  equal  variance  Student’s  t  test.  Data  for 
comparison of multiple groups are presented as mean 
 SD and were analyzed by ANOVA. *p < 0.05 was 
considered statistically significant. 
Case Report 
A very active, athletic 61 year-old male with well 
controlled  coronary  artery  disease  presented  in  late 
2001 with recurrent episodes of severe epigastric pain 
associated with elevation of his serum lipase levels. A 
clinical suspicion of chronic cholecystitis led to a lap-
aroscopic cholecystectomy without clinical benefit. In 
April 2003, an endoscopic ultrasound showed mini-
mal  dilatation  of  the  pancreatic  and  common  bile 
ducts,  and  an  endoscopic  retrograde  cholangiopan-
creatography (ERCP) with sphincterotomy was per-
formed with unremarkable findings and with no ad-
ditional benefit.  
In  September  2003,  two  years  after  his  initial 
presentation, an MRI demonstrated a 1.5 cm lesion at 
the junction of the body and tail of the pancreas, as 
well as a 1 cm lesion in the hepatic dome. Repeat en-
doscopic ultrasound demonstrated an ill-defined hy-
poechoic  area  in  the  body  of  the  pancreas,  with  a 
non-diagnostic fine needle aspiration.  
In October 2003 the patient underwent explora-
tory  laparotomy  with  distal  pancreatectomy  and 
splenectomy.  Intraoperative  ultrasound  showed  a  3 
cm liver lesion. Final pathology revealed a 6.5 cm high 
grade acinar cell carcinoma of the pancreas. Relevant Journal of Cancer 2011, 2 
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blood  chemistries  revealed  highly  elevated  serum 
lipase  prior  to  surgery  (Table  1).  Because  of  tumor 
involving  the  margin  of  resection,  further  resection 
was performed, with focal involvement noted. Sub-
sequent fine needle aspiration of the liver lesion con-
firmed metastatic disease. As this was the sole meta-
static site, the lesion was treated with radiofrequency 
ablation. Adjuvant treatment consisted of 3 cycles of 
gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) 
followed by radiation (4500 cGy) to the pancreatic bed 
concomitantly with five weekly cycles of cisplatin (40 
mg/m2), completed in March 2004. 
Restaging evaluation on April 2004 showed two 
new liver lesions, which were treated with radiofre-
quency  ablation.  This  was  followed  by  5  cycles  of 
weekly paclitaxel 80 mg/m2 with thalidomide 100 mg 
daily, completed on May 2004. Thalidomide was dis-
continued July 2004 due to the development of deep 
vein thrombosis. The patient did well until February 
2005 when he developed new liver metastases. Cape-
citabine  1000  mg  orally  twice  daily  for  two  out  of 
every three weeks was initiated then. Serum lipase, 
CEA and alkaline phosphatase levels were monitored 
over this period and reflected active disease (Table 1). 
In May 2005, biopsies of his stable liver lesions 
were  performed  for  gene  microarray  and  immuno-
histochemistry analysis to identify altered genes that 
are potential targets (Table 2). A number of gene tar-
gets were identified to be over-expressed or present in 
the patient’s liver lesion that included carboxylester-
ase 2 (CES2), topoisomerase IIB (TOP2B), deoxycyti-
dine kinase (DCK), and nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor alpha 
(NFKBIA).  Immunohistochemistry  (IHC)  for 
HER2/neu, estrogen receptor (ER), progesterone re-
ceptor  (PR),  c-kit,  epidermal  growth  factor  receptor 
(EGFR) and cyclooxygenase 2 (COX-2) demonstrated 
positivity only for c-kit (Table 2). From the same bi-
opsy tissue used for genomic analysis, primary cells in 
culture were also developed for drug testing. From 
this list of genes, FDA approved drugs known to tar-
get the protein products of these genes (Table 2) were 
tested  in  the  patient’s  cells  derived  from  the  meta-
static liver lesion (Figure 1). These drugs included the 
following:  STI-571  (C-kit  tyrosine  kinase  inhibitor), 
bortezomib  (proteosome  inhibitor),  doxorubicin, 
etoposide and cytosine arabinoside. Using drug doses 
physiologically  relevant  to  humans  demonstrated  a 
strong inhibition of cell growth and cell death (>70% 
inhibition)  was  identified  for  all  but  etoposide  and 
cytosine arabinoside (Figure 1). 
Table 1. Serum Lipase, CEA, Alkaline Phosphatase levels linked to clinical events. 
Date  Event  Lipase 
 (u/L)  
CEA 
(ng/ml)  
Alpha  feto-
protein 
ng/ml  
Alk. Phos. 
(IU/L)  
Oct/2003   Prior to pancreatectomy  100  N/A  N/A  121 
Oct/2003  Post pancreatectomy and RFA  32  N/A  6.4  129 
April 2004  Post Chemoradiation/Two new 
liver mets. 
  0.6  14.2  101 
April 2004  Post radioablation of liver mets.  13  0.5  8.7  121 
August 2004  Post paclitaxel/thalidomide  12  0.5  7.0  116 
Feb/2005  Two new liver 
mets/Capecitabine initiated 
  1.2  8.2  130 
August/2005  Capecitabine treatment discon-
tinued with worsening disease 
    7.8  240 
2006  Before doxorubicin  2027  1.5    374 
2006  During doxorubicin  90  3.2  5.8  190 
2007  Before intra-arterial brachy-
therapy with Sirspheres 
100  3.4  6.3  179 
2007  After intra-arterial brachy-
therapy with Sirspheres 
31  3.5  14.1  457 
Jan 2008  Before radiofrequency ablation  75  3.4  13.2  382 
Jan 2008  After radiofrequency abla-
tion/before cryotherapy 
110  3.3  9.5  368 
July 2008  progression of liver lesions and 
development of mesenteric 
lesions 
150  3.4  8.9  431 
Nov 2008  Before external beam radiation 
to a progressive liver lesion 
222  4.1  9.8  583 
January 2009  hepatic and mesenteric disease 
had worsened 
682    7.4  609 
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Table 2. May 2005: Upregulated genes, protein, and matching FDA approved drugs identified from liver biopsy of ACC 
tumor. 
Gene  Fold Increase  Possible Interacting gene 
CES2  3.09  Irinotecan (topoisomerase 1 inhibitor) 
TOP2B  2.77  Etoposide, Doxorubicin, Doxil 
NFKBIA  2.50  Bortezomib (proteosome inhibitor) 
DCK  2.14  Cytarabine (antimetabolic agent) 
     
Protein  IHC Intensity/% cells staining positive   Possible Interacting agent 
c-kit  +2/100%  Imatanib (tyrosine kinase inhibitor) 
 
 
 
 
Figure 1. Cell culture screening using FDA approved drugs which were identified from genomic profiling and IHC data 
showed inhibition of cell proliferation of patient's acinar cell pancreatic carcinoma cell line. Drugs were selected based upon 
gene array (Incyte) and immunohistochemistry data that identified druggable molecular targets present in the tumor known 
to be a molecular target for each drug. Cells established from a liver biopsy of the patient’s tumor tissue were plated at 2 x 
10
4 cells/ml/well on day 0 and treated with the indicated drugs and concentrations on day 1. Media was changed every 48 hrs 
along with addition of new drugs. On day 6, cells were photographed at 20x magnification and counted using a Coulter 
Counter. Data are expressed as the mean and S.D. * indicates statistical difference from Control (P< 0.05). 
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The liver lesions worsened in August 2005 and 
capecitabine  was  discontinued  in  favor  of  imatinib 
400 mg twice daily based on positive IHC for c-kit in 
the patient’s biopsy tissue (Table 2). The patient had 
transient improvement in some of his lesions with this 
therapy but progressed by October 2005 with the de-
velopment of skin lesions as well as worsened hepatic 
lesions. Imatinib was discontinued and etoposide 50 
mg  daily  was  initiated.  Although  after  a  month  of 
therapy, the liver lesions improved, skin lesions pro-
gressed.  
In view of the results from the patient’s biopsy 
demonstrating  elevated  topoisomerase  II  mRNA 
(Table  2)  and  growth  inhibition  by  doxorubicin 
(topoisomerase II inhibitor) in the patient’s cell line 
(Figure 1), he was subsequently started on liposomal 
doxorubicin (40 mg/m2 every three weeks) through 
most of 2006 with excellent partial response (Figure 
2). An index lesion in the liver was chosen and SUV 
on  10/18/05  averaged  6.4.  One  year  later  after  the 
liposomal  doxorubicin  treatment,  the  SUV  average 
decreased substantially to 2.1. 
After  16  cycles  of  this  treatment,  with  no  evi-
dence  of  metastatic  progression,  the  treatment  was 
discontinued due to the potential for cardiac toxicity 
associated with cumulative doses of doxorubicin. Pa-
tient’s cardiac function remained normal. 
The patient then underwent hepatic intra-arterial 
brachytherapy with Sirspheres in February 2007. An 
isolated progressive liver lesion was treated with ra-
diofrequency ablation in January 2008; this area was 
re-treated with cryotherapy in April 2008 due to re-
sidual disease. For these three procedures, lipase and 
relevant chemistries are shown in Table 1. 
The patient received stereotactic radiosurgery to 
a  pericardial  lymph  node  in  May  2008.  However, 
prior  to  stereotactic  radiosurgery,  the  patient  re-
quested  another  biopsy  of  the  lymph  node  for  the 
purpose of performing gene array analysis, immuno-
histochemistry and development of a new cell line for 
the purpose of identifying drug targets and potential 
therapeutic  drugs.  The  thought  was  that  the  tumor 
had evolved into a more aggressive phenotype with 
underlying  oncogenic  changes  in  the  genome  and 
proteome. Biopsy yielded tissue for genomic and IHC 
analysis. IHC data now revealed positive staining for 
excision  repair  cross-complementing  rodent  repair 
deficiency, complementation group 1 (ERCC1), dihy-
drofolate reductase (DHFR),  thymidylate synthetase 
(TYMS),  PR,  acidic  cysteine-rich  secreted  protein 
(SPARC,  osteonectin)  Epidermal  growth  factor  re-
ceptor (EGFR), platelet derived growth factor receptor 
(PDGFR) and topoisomerase (DNA) II alpha (TOP2A) 
(Table 3).  
 
Figure 2. PET scan demonstrates tumor improvement while on liposomal doxorubicin treatment. A. Patient’s PET scan 
prior to liposomal doxorubicin, and B. Patient’s PET scan after 16 cycles (1 cycle = 3 weeks) of liposomal doxorubicin 
demonstrated shrinkage of tumor with treatment. Note the significant improvement in liver lesions as well as a left upper 
extremity skin lesion. Arrows indicate tumor lesions with notable reduction with treatment. In the central liver in the region 
of the caudate lobe there is a lesion which was present on 10/18/05 but no longer seen on 10/23/06 [Standardized Uptake 
Values (SUV) 10/18/05: Average 6.4, Max 8.3. 10/23/06: Average 2.1, Max 2.6]. In the periphery of the anterior segment of 
the right lobe there is a lesion which was large on 10/18/05 and much smaller on 10/23/06 [SUV 10/18/05: Average 3.2, Max 
4.4. 10/23/06: Average 3.0, Max 3.5].  Journal of Cancer 2011, 2 
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Table 3. May 2008: Upregulated genes, proteins, and matching FDA approved drugs identified from liver biopsy of ACC 
tumor. 
Protein  IHC Intensity/% cells 
staining positive 
 Posible Interacting agent 
PR  +2/60%  Exemestane, fulvestrant, gonadorelin, goserelin, 
medroxyprogesterone, megestrol, tamoxifen, torem-
ifene 
SPARC   +2/60%  Paclitaxel albumin-bound 
EGFR  +2/60%  Lapatinib, erlotinib, getifinib, cetuximab, pani-
tumumab, dasatinib  
PDGFR  +2/50%  Imatinib, sorafenib, sunitinib 
TOP2A   +2/30%  Doxorubicin, epirubicin, etoposide, mitoxantrone, 
teniposide 
HSP90   +2/30%  CNF2024, 17-AAG 
c-kit  +1/40%  Imatinib 
P-glycoprotein  +2/30%  Ixabepilone  
     
Gene  Fold Increase  Possible Interacting Agent  
TOP2A  90.92  Doxorubicin, epirubicin, etoposide, mitoxantrone, 
teniposide 
GART   3.72  Pemetrexed 
ADA   2.72  Cytarabine, pentostatin 
HSP90AA1  2.57  CNF2024 
SPARC  2.53  Paclitaxel albumin-bound 
TOP1   2.52  Irinotecan, topotecan 
YES1   2.08  dasatinib 
HIF1A  1.80  Sorafanib, sunitinib, bevacizumab 
     
Drug resistant Genes/Proteins  Fold Increase or IHC 
positivity 
Drug resistance 
TYMS   15.81  Capecitabine and fluorouracil 
DHFR    5.34  Methotrexate 
P-glycoprotein  +2/30%  Paclitaxel, doxorubicin, etoposide, epirubicin, docet-
axel, vinblastine, vinorelbine, topotecan, teniposide 
 
 
ERCC1 over-expression raises the possibility of 
resistance  to  carboplatin,  cisplatin  and  oxaliplatin. 
DHFR was over-expressed raising the possibility  of 
resistance to methotrexate. TYMS was over-expressed 
15.81-fold showing a possible resistance to capecita-
bine  and  fluorouracil.  Other  proteins  examined  by 
IHC  that  were  negative  include  Her2/neu,  ER,  an-
drogen receptor (AR), CD52, CD25 and survivin. As 
well,  gene  array  data  revealed  upregulation  of  a 
number of new gene targets not identified in the pro-
file performed 3 years previously in May 2005 (Table 
3). These genes are Topoisomerase II (TOP2), phos-
phoribosylglycinamide  formyltransferase  (GART), 
adenosine  deaminase  (ADA),  heat  shock  protein 
90kDa alpha class A member 1 (HSP90AA1), SPARC, 
topoisomerase I (TOP1), v-yes-1 Yamaguchi sarcoma 
viral oncogene homolog 1 (YES) and hypoxia induci-
ble factor 1 alpha (HIF1A). 
Primary  cells  were  established  in  cell  culture 
from the lymph node metastasis (Panc-4). These cells 
were tested with some of the drugs listed in Table 3. 
Lipase  levels  measured  in  the  media  of  confluent 
Panc-4 cells exchanged at 48 hours was 137 U/L. The 
control media measured 1 U/L, thus validating that 
both lesions were pancreatic acinar cell carcinoma. As 
shown  in  Figure  3A,  Panc-4  cells  were  tested  for 
growth inhibition using lapatinib, ixabepilone or the 
combination of the two together. Monotherapy results 
in a dose responsive decrease in cell number as the 
concentration of each drug is increased. Using a fixed 
ratio of the two drugs at or above the IC50s for each 
compound, synergy was demonstrated (Figure  3A). 
The  calculated  CI  values  were  0.44  for  500nM:2nM 
concentrations of lapatinib:ixabepilone, 0.43 for the 1 
µM:4.0  nM  doses  and  0.45  for  the  2000  nM:16  nM 
doses. In Figure 3B, Lapatinib and dasatinib (src in-
hibitor) were tested alone and together for antitumor 
synergy in Panc-4 cells and found to be synergistic in 
the median dose ranges (0.1 μM:10 nM, 2 μM:20nM & 
3 μM:30 nM) with CI values of 0.72, 0.78 and 0.94 re-
spectively  (Figure  3B).  The  proteosome  inhibitor, 
bortezomib, was examined in combination at a fixed Journal of Cancer 2011, 2 
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ratio  of  100:1  (bortezomib:17-AAG)  with  the  hsp90 
inhibitor, 17-AAG (Figure 3C). Synergy was demon-
strated  at  higher  concentrations  with  the  650nM 
17-AAG:6.5 nM bortezomib doses demonstrating a CI 
value  of  0.84  while  800  nM:8  nM  doses  yielded  CI 
value of 0.75 and the 1000 nM:10 nM doses yielding a 
CI value of 0.67. 
 
Figure 3. ACC Lymph node metastatic tumor cells respond to drug therapies and demonstrate antitumor synergy in 
combination. A. Panc-4 cells were plated at 2 x 10
4 cells/ml in 12-well plates and treated the following day with lapatinib, 
ixabepilone or both at the indicated concentrations. Cell number was calculated and combinatorial drug synergy determined 
as described in Materials and Methods. B. Panc-4 were treated with lapatinib and/or dasatinib at the indicated doses and 
examined for drug synergy as described above. C. Panc-4 were treated with bortezomib and/or 17-AAG at the indicated 
doses and examined for drug synergy as described above. Journal of Cancer 2011, 2 
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Table 4. Serum lipase levels from ACC tumor grown in athymic nude mice. 
Tumor  Implant date/ 
harvest date 
Tumor volume 
 (mm3) 
Lipase levels (U/L) 
(low  limit  of  detection  =  3 
U/L) 
Panc 4  4/25/08-12/18/08  180  Blood not drawn 
*Panc 4-1  12/18/08-6/26/2009  745  811 
*Panc 4-2  10/2/09-4/22/10  210  188 
*Panc 4-3   1/8/10-4/22/10  920   1731 
*- Successive passage of tumor from the preceding tumor. 
 
 
 
An in vivo model was also established, whereby 
tumor  tissue  was  implanted  directly  into  athymic 
nude mice subcutaneously into the right hind flank. 
This was indicative that the biopsied metastatic tumor 
lesions had become more aggressive when compared 
to  the  previous  biopsy  in  May  2005  which  did  not 
establish  tumors  when  implanted  into  mice.  These 
tumors  have  been  passaged  continuously  now  for 
over two years and continue to secrete lipase into the 
blood (Table 4). Cumulatively the genomic, IHC and 
cell  models  are  indicative  that  the  tumor  had  pro-
gressed  to  a  more  aggressive  phenotype  from  the 
previously biopsied tumor tissue. 
In July 2008, there was progression of liver le-
sions and development of mesenteric lesions. He was 
started  on  sorafenib  (tyrosine  kinase  inhibitor)  and 
temozolomide  (alkylating  agent)  until  progression 
November 2008. He received external beam radiation 
to  a  progressive  liver  lesion  in  November  2008.  As 
indicated in Table 1, lipase levels are shown during 
this period of treatment between July to November 
2008. 
His  hepatic  and  mesenteric  disease  had  wors-
ened  by  January  2009  so  he  was  initiated  on  albu-
min-bound  paclitaxel  (Abraxane)  100  mg/m2  and 
bevacizumab 5 mg/kg. Despite improvement in his 
serum  lipase  levels  (Table  1),  albumin-bound 
paclitaxel  was  discontinued  after  two  doses  due  to 
progressive  neuropathy.  Bevacizumab  was  discon-
tinued after three doses due to progressive confusion 
and further therapy was declined. The patient expired 
in July 2009 from complications related to progression 
of metastatic ACC.  
Discussion 
A  multi-disciplinary  approach,  with  the  con-
certed efforts of surgeons, interventional radiologists, 
radiation oncologists, medical oncologists, as well as 
the  efforts  of  basic  scientists  working  with  the  pa-
tient’s cell line was associated with an 8 year survival 
of this patient. Moreover, the patient enjoyed a very 
good  quality  of  life  with  his  treatments  as  well, 
maintaining his very active lifestyle until shortly be-
fore his death.  
How does our patient’s experience compare with 
others? Like the established literature showing male 
predominance and younger age at presentation8, our 
patient was a male in his early 60’s at the time of di-
agnosis. Also consistent with the  literature,  our pa-
tient had better survival time than would be expected 
with a pancreatic adenocarcinoma. Table 5 provides a 
brief summary of ACC patient characteristics from a 
few retrospective studies. A review of the Mayo Clinic 
Tumor  Registry  has  shown  42  patients  diagnosed 
with ACC from 1972 through 2009. A male predomi-
nance and younger age at diagnosis was observed in 
the Mayo Clinic series (Table 5).  
As  mentioned,  case  reports  and  retrospective 
reviews do show extended survival in many patients 
with resectable disease, and in some with metastatic 
disease at presentation. Although published reports 
are  few,  survival  beyond  a  few  months  in  patients 
with metastatic disease is noted in patients managed 
with localized procedures such as metastasectomies. 
Chemotherapies such as 5-fluorouracil, capecitabine, 
or  gemcitabine  combined  with  radiation  have  been 
used with some success2, 7, 18, 21. Case reports of meta-
static  patients  managed  with  systemic  treatments 
show mixed responses to treatment  17-26. Considered 
the standard of care for pancreatic adenocarcinoma, 
palliative treatment with gemcitabine, either alone or 
as combination therapy, has shown benefit in some 
reports  but  disappointing  in  others17,  22,  24,  25.  Some 
activity  has  been  noted  with  5-fluorouracil2,  19  and 
paclitaxel  (present  study23).  Because  of  the  small 
number of cases, it is difficult to draw definitive con-
clusions  regarding  the  best  approach  to  systemic 
therapy. 
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Table 5. Retrospective review of patients diagnosed with ACC. 
Study  Patient  Num-
ber, % male 
Median 
Age  
Median  Sur-
vival (months) 
 
Median Tumor size  Metastasis  at 
diagnosis 
Mayo Clinic  42, 64%  59.5  Data not 
available 
Data not available  37.5% 
Klimstra DS, et al.1   28, 86%  62 (mean)  18.1 (mean)  10.8 cm (mean)  50% 
Holen KH, et al.2  39, 77%  60  19  Data not available  49% 
Kitagami H, et al.3  115, 67%  59.6 (mean)  41  Data not available  28.7% 
Wisnoski NC, et al.8  672, 54%  56.7 (mean)  47  Data not available  53.1% 
Seth AK, et al.7  14, 36%  57  33  3.9 cm  14.3% 
Matos JM, et al.5  17  59  19  5.3 cm  17.6%  
 
 
Why did our patient, unlike the vast majority of 
ACC patients metastatic at presentation, have such a 
prolonged survival? We believe there were two major 
contributing  factors.  Like  previously  described  re-
ports, our patient benefitted from an aggressive mul-
ti-disciplinary  approach,  with  surgical  management 
of his primary tumor and localized interventions for 
his  metastases.  Also  like  previous  reports,  disease 
control  with  empiric  systemic  treatments  was  at-
tempted, with mixed results. However, we believe the 
second major contributing factor was moving beyond 
empiric  systemic  treatment  approaches  to  systemic 
therapies based on translational studies performed on 
the  patient’s  own  tumor  cell  line  derived  from  his 
metastatic tumor tissues. Utilizing the patient’s own 
tumor cells takes into account specific genomic and 
epigenetic  alterations  that  will  modify  response  to 
therapy.  Utilizing  this  approach  combined  with  ge-
nomics and proteomics, drugs may be identified and 
tailored as combinatorial therapy leading to individ-
ualized medicine. Because of these studies, doxorubi-
cin was selected and offered a dramatic and durable 
response. To our knowledge this is the first report of 
doxorubicin being used for ACC. Doxorubicin does 
not have a role in the management of pancreatic ad-
enocarcinoma. Whether the success of doxorubicin in 
our patient could be extrapolated to ACC in general 
or whether its success is specific to our patient in par-
ticular is of course not known. Also we should note, as 
can be expected, the correlation between cell line re-
sponse  and  patient  response  is  not  perfect,  as  is 
demonstrated by our patient’s mixed and only tran-
sient response to imatinib. Although not perfect, the 
combined genomics, proteomics and drug testing in 
the  patient’s  cells  over  time  demonstrated  that  this 
ACC tumor evolved at the gene and protein level into 
a  more  aggressive  tumor  with  multiple  enhanced 
oncogenic signaling pathways being turned on. 
 This  case  demonstrates  the  possibility  of  ex-
tended  survival  of  approximately  8  years  after  the 
diagnosis  of  metastatic  acinar  cell  carcinoma  of  the 
pancreas  with  an  aggressive  multi-modality  thera-
peutic  approach  (surgical,  radiation  and  systemic 
treatments) directed by genomic profiling of the pa-
tient’s tumor identifying  druggable gene alterations 
coupled with demonstrating antiproliferative activity 
in the patient’s own tumor cell line in response to the 
identified molecular therapeutics. The extended sur-
vival was feasible by the observed excellent responses 
obtained by tailoring treatment based on in vitro cell 
culture responses to imatinib and liposomal doxoru-
bicin  of  the  patient’s  tumor  cells.  A  translational 
strategy,  from  bench  to  bedside,  may  lead  to  im-
proved  outcomes  for  individual  patients  with  less 
common malignancies, where there may be a paucity 
of  evidence-based,  prospective  data  to  otherwise 
guide management. 
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